Biotech Mailbag: Transdel Pharma
Readers touch base with Adam on Transdel Pharma, Vivus, Genta, Cel-Sci and more.
06:00AM 10/09/09
Biotech Mailbag: Cel-Sci, BioElectronics
Readers weigh in on Cel-Sci, BioElectronics, Dendreon, Cell Therapeutics and more.
09:18AM 10/02/09
Biotech Mailbag: Cel-Sci, BioElectronics
Readers weigh in on Cel-Sci, BioElectronics, Dendreon, Cell Therapeutics and more.
08:34AM 10/02/09
Biotech Mailbag: Cel-Sci, BioElectronics
Readers weigh in on Cel-Sci, BioElectronics, Dendreon, Cell Therapeutics and more.
06:56AM 10/02/09
Biotech Mailbag: Cel-Sci, BioElectronics (RealMoney.com $)
Readers weigh in on Cel-Sci, BioElectronics, Dendreon, Cell Therapeutics and more.
06:00AM 10/02/09
Biotech Stock Mailbag: Geron, Oculus, BioSante
Geron, Oculus, BioSante, Gilead Sciences and Sequenom are among readers' stocks of interest in this special edition mailbag.
11:45AM 08/19/09
Biotech Stock Mailbag: Fans Rally 'Round Arena
Arena fans take issue with a column outlining the company's challenges.
07:59AM 03/27/09
Teva Ticks Up on Biogeneric Deal
Teva and contract drug manufacturer Lonza Group are teaming up to make and market copies of biotech drugs.
03:33PM 01/20/09
Biotech Scorecard: My Best and Worst Calls
Biotech expert Adam Feuerstein grades his hits and misses for 2008.
06:59AM 01/02/09
Here's a look back at the hits, misses and notable moments from 2008.
12:20PM 12/29/08
Elan's Martin Named Worst Biotech CEO of '08
Kelly Martin is taking home the Nance Trophy for oustanding achievement in loss of shareholder value, overstated optimism and abject incompetence under pressure.
10:44AM 12/11/08
Biotech Stock-Picking: Incyte, Celgene
How much do you know about investing in biotech companies? Go beyond the hype with TheStreet.com
06:37PM 10/27/08
Biotech Mailbag: Lessons From Clinical Trials
Senior Columnist Adam Feuerstein's column on Cell Genesys elicited some compliments -- and some negative mail from Dendreon fans.
04:10PM 10/24/08
Biotech Mailbag: Lessons From Clinical Trials (RealMoney.com $)
Senior Columnist Adam Feuerstein's column on Cell Genesys elicited some compliments -- and some negative mail from Dendreon fans.
08:09AM 10/24/08
Don't Get Burned by the Next Cell Genesys
Senior Columnist Adam Feuerstein re-examines the red flags in the Cell Genesys story so that when the same issues rear their ugly head in another biotech story investors will be better prepared.
10:00AM 10/20/08



Connect with TheStreet